Peoples Bank KS Has $50,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Peoples Bank KS reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 252 shares of the medical research company’s stock after selling 50 shares during the quarter. Peoples Bank KS’s holdings in IQVIA were worth $50,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Simplify Asset Management Inc. grew its stake in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Versor Investments LP bought a new position in IQVIA in the third quarter valued at approximately $1,328,000. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its stake in IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Morgan Stanley reduced their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Robert W. Baird lowered their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Finally, BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Price Performance

Shares of IQV opened at $202.63 on Wednesday. The business has a 50-day moving average of $202.22 and a 200-day moving average of $221.94. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a market capitalization of $36.78 billion, a price-to-earnings ratio of 26.59, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.